Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

Despite intensive multimodal therapy, the survival rate for high risk neuroblastoma (HR-NB) remains <50%. Most cases initially respond to treatment but almost half will subsequently relapse with aggressive treatment resistant disease. Novel treatments exploiting the molecular pathology of NB and/...

Descripción completa

Detalles Bibliográficos
Autores principales: Southgate, Harriet E. D., Chen, Lindi, Curtin, Nicola J., Tweddle, Deborah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145987/
https://www.ncbi.nlm.nih.gov/pubmed/32309213
http://dx.doi.org/10.3389/fonc.2020.00371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145987/
https://www.ncbi.nlm.nih.gov/pubmed/32309213
http://dx.doi.org/10.3389/fonc.2020.00371

Ejemplares similares